Add time:09/24/2019         Source:sciencedirect.com

Gitalin, the water-soluble, amorphous mixture of glycosides extractable from Digitalis purpurea, was isolated by Kraft1 in 1912. Under the names of Gitalin-Kraft in Germany, Digisol in Holland, and verodigen in this country and abroad, this digitalis preparation had been subjected to considerable pharmacological, as well as clinical, investigation. It was the concensus that gitalin possessed many of the properties of digitalis leaf or digitoxin and that with appropriate dosage one could utilize gitalin wherever digitalization was indicated. The American investigators, Stroud and associates,2 Baker and Bloom,3 and Levy and Boas,4 concluded that gitalin was just another digitalis preparation which could be used in place of those currently available. On the other hand, the German investigators,5 notably Straub and Krehl,5a expressed the opinion that gitalin was superior to other digitalis preparations. The reasons for this were vague and reflected impressions rather than pharmacological or clinical data. In view of this divergence of opinion between the American and German investigators, it was thought advisable to restudy this digitalis preparation. The purpose of this paper is to present our studies with amorphous gitalin for the treatment of congestive heart failure in comparison with our previous experiences with other cardiac glycosides.

We also recommend Trading Suppliers and Manufacturers of Gitalin (amorphous) (cas 1405-76-1). Pls Click Website Link as below: cas 1405-76-1 suppliers